
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics is a commercial-stage medical diagnostics technology company that is currently in its early stage of commercialization. It is focused on patients with gastroesophageal reflux disease (GERD), which puts them at risk for developing esophageal precancer and cancer. The company's two main products, EsoCheck and EsoGuard, have been supported by leading gastroenterology specialty associations and are seen as an acceptable alternative to endoscopy. Lucid plans to ramp up commercialization and gain approval for Medicare coverage, which we believe will be catalysts for the stock. The company reported Q1 results slightly lower than expected, but we believe revenue will significantly increase in 2026/27. With an attractive current valuation and multiple growth levers ahead, we are optimistic about the company's potential success, although there are risks involved such as uncertainties with reimbursement and commercial execution. There is also potential competition in the market, but parallels can be drawn between Lucid's EsoGuard test and Exact Sciences' Cologuard test, which has seen significant success.
Bears say
Lucid Diagnostics is a commercial-stage medical diagnostics technology company that focuses on patients with reflux disease who are at risk of developing esophageal precancer and cancer. While the company has received support from medical associations and is expected to receive Medicare coverage, there are risks to achieving projected sales, including regulatory approvals, competition, and changes in healthcare priorities. Additionally, the company may need to increase its sales force to meet its targets and has yet to achieve significant payor coverage, which could limit its potential for growth. Ultimately, there are several potential barriers that could impact the company's financial success.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares